Philadelphia positive (Ph+) chronic myeloid leukaemia (CML) presenting synchronously or following non-Hodgkin lymphoma (NHL) has only rarely been reported. Herein, we refer on a case of Ph+ CML occurring after a breast cancer and a NHL with multiple relapses. After obtaining complete cytogenetic remission with imatinib, the patient presented a new NHL relapse, that was treated with rituximab concomitantly to imatinib. Therapy was well tolerated and the patient is presently alive in complete remission of either NHL and CML. We also reviewed the literature relating the uncommon association of these two unrelated diseases.
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma / Breccia, M; Martelli, Maurizio; Cannella, L; E., Russo; Finolezzi, E; Stefanizzi, Caterina; Levi, A; Frustaci, A; Alimena, Giuliana. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 32:(2008), pp. 353-355. [10.1016/j.leukres.2007.07.023]
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma.
BRECCIA M;MARTELLI, Maurizio;STEFANIZZI, CATERINA;ALIMENA, Giuliana
2008
Abstract
Philadelphia positive (Ph+) chronic myeloid leukaemia (CML) presenting synchronously or following non-Hodgkin lymphoma (NHL) has only rarely been reported. Herein, we refer on a case of Ph+ CML occurring after a breast cancer and a NHL with multiple relapses. After obtaining complete cytogenetic remission with imatinib, the patient presented a new NHL relapse, that was treated with rituximab concomitantly to imatinib. Therapy was well tolerated and the patient is presently alive in complete remission of either NHL and CML. We also reviewed the literature relating the uncommon association of these two unrelated diseases.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
